cas 109-07-9|| where to buy 2-Methylpiperazine

Nom du produit:2-Methylpiperazine

IUPAC Name:2-methylpiperazine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM120079-100g	in stock	ɅȬ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:109-07-9; Formule moléculaire:C5H12N2; Point de fusion:-; Code SMILES:CC1NCCNC1; Densité:

: Numéro de catalogue:CM120079; Poids moléculaire:100.17; Point d'ébullition:; N° Mdl:MFCD00005954; Stockage:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Fuel Cell Materials; Fuel Cells is a highly efficient, clean and renewable energy technology with many advantages such as low emissions, high efficiency, quiet operation and flexibility. They can use many different fuels, such as hydrogen, methanol, natural gas and biomass, making them highly adaptable and flexible. Fuel cell materials are essential components in the construction and operation of fuel cells, which are devices that convert chemical energy from fuels into electrical energy through an electrochemical process. There are several types of fuel cells, such as proton exchange membrane fuel cells (PEMFCs), solid oxide fuel cells (SOFCs), and molten carbonate fuel cells (MCFCs), each requiring different materials for their functioning.

: Fenebrutinib; Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.